BTK and B-cell chronic lymphocytic leukemia: Along similar lines, at least part of the clinical activity of ibrutinib (PCI-32765), a small molecule inhibitor of bruton tyrosine kinase (BTK) recently approved by the US FDA for use in patients with MCL and CLL [500-502], may stem from its ability to target tumor-infiltrating B lymphocytes or myeloid cells [503].